No­var­tis nix­es PhII TGFß an­ti­body — and one-time 'wild card' — af­ter ben­e­fit-risk as­sess­ment

Eight years af­ter No­var­tis first li­censed an an­ti-TGFß an­ti­body from XO­MA, the Swiss phar­ma gi­ant is wind­ing down all de­vel­op­ment.

The drug, dubbed NIS793, was be­ing test­ed in two Phase II tri­als. As part of its quar­ter­ly earn­ings in Ju­ly, No­var­tis dis­closed it was cut­ting the study in metasta­t­ic pan­cre­at­ic duc­tal ade­no­car­ci­no­ma, “based on ben­e­fit-risk as­sess­ment.” It’s now shut­ting down a sep­a­rate col­orec­tal can­cer tri­al, which it pre­vi­ous­ly said would con­tin­ue. XO­MA first re­vealed the pro­gram ter­mi­na­tion in an SEC fil­ing Fri­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER